Beam Therapeutics (MEX:BEAM) LT-Debt-to-Total-Asset: 0.16 (As of Mar. 2026)

What is Beam Therapeutics LT-Debt-to-Total-Asset?

Beam Therapeutics MEX:BEAM 66 LT-Debt-to-Total-Asset is 0.16 as of Mar. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 66/100 and a GF Value™ of MXN525.92 (Modestly Overvalued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Beam Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.16.

Beam Therapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.10) to Mar. 2026 (0.16). It may suggest that Beam Therapeutics is progressively becoming more dependent on debt to grow their business.

Beam Therapeutics (MEX:BEAM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Beam Therapeutics LT-Debt-to-Total-Asset Related Terms

Beam Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics LT-Debt-to-Total-Asset Chart

Beam Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

0.13

0.11

0.13

0.09

Beam Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.10	0.10	0.11	0.09	0.16

66GF Score

Beam Therapeutics Inc MEX:BEAM

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Beam Therapeutics LT-Debt-to-Total-Asset Calculation

Beam Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	2516.459	/	26669.629
	=	0.09

Beam Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	4256.457	/	26702.786
	=	0.16

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.16 mean?

Beam Therapeutics (MEX:BEAM) has a LT-Debt-to-Total-Asset of 0.16 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Beam Therapeutics and its competitors.

Is Beam Therapeutics' LT-Debt-to-Total-Asset too high?

Beam Therapeutics' current LT-Debt-to-Total-Asset is 0.16. Overall, Beam Therapeutics has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Beam Therapeutics' LT-Debt-to-Total-Asset compare to ELVN and IDYA?

Beam Therapeutics' LT-Debt-to-Total-Asset of 0.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current LT-Debt-to-Total-Asset is 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Beam Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN525.92, compared to a current price of MXN628.46 — trading 19.5% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.16. Beam Therapeutics' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current LT-Debt-to-Total-Asset is 0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN628.46 is trading 19.5% above its estimated GF Value™ of MXN525.92. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for MEX:BEAM:

LT-Debt-to-Total-Asset: 0.16
GF Value™: MXN525.92 vs. price of MXN628.46 (19.5% above fair value)
GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ELVN IDYA PBLS DYN ARQT ALMS CPRX CRNX NAMS QURE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges BEAM:USA

Address 238 Main Street, Cambridge, MA, USA, 02142

Website https://www.beamtx.com

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

66GF Score

Get the complete analysis for MEX:BEAM

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN628.46

Price

MXN525.92

GF Value

View MEX:BEAM Analysis

See LT-Debt-to-Total-Asset data for all stocks →